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A B S T R A C T
Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease characterized by the fibrotic thick-
ening of subpleural and parenchymal areas of the upper lobes. It may be both idiopathic or secondary to in-
fections, interstitial lung diseases and/or drug exposure. Often PPFE patients report recurrent lower respiratory
tract infections, suggesting that repeated inflammatory alterations induced by pulmonary infections may con-
tribute to the development/progression of PPFE.
Here, we report for the first time the case of a patient affected by Giant cell Arteritis with histologically
proven PPFE. The lung involvement in GCA is rare and interstitial lung diseases are usually reported as an
uncommon clinical manifestation of GCA. Our patient is probably the first case presenting PPFE associated with
GCA and we wonder if this is a real associative disease or a coincidence perhaps, secondary to drug effects.
1. Introduction
Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung
disease (ILD) characterized by a fibrotic thickening of subpleural and
parenchymal areas of the upper lobes [1]. It was firstly described in
1992 [2] and, according to updated ATS/ESR guidelines [3], PPFE can
be considered an idiopathic ILD with no clear relationship with
smoking exposure [4,5]. PPFE may be associated with infections, in-
terstitial lung diseases and/or drug exposure. PPFE can occur conse-
quently to lung, bone marrow, hematopoietic cell transplantation [6],
immunosuppressive treatments [7,8] or occupational exposures to si-
licate dust and asbestos [9]. Often, PPFE patients report recurrent lower
respiratory tract infections, suggesting that repeated inflammatory in-
juries induced by pulmonary infections may contribute to the patho-
genesis of PPFE. The disease may also be associated with different ILDs,
including idiopathic pulmonary fibrosis (IPF) and hypersensitivity
pneumonitis (HP) [10–12]. Especially in young females, PPFE can occur
in the context of familial forms of idiopathic interstitial pneumonias
(IIP), suggesting a potential role of a genetic predisposition in its de-
velopment [13,14]. Common symptoms of PPFE include dyspnea, dry
cough and weight loss; in the course of the disease some patients can be
affected by spontaneous pneumothorax [5,16]. As a rule, PPFE is as-
sociated with a restrictive functional deficit and an impairment of CO
diffusion capacity (DLCO) [5], which are considered the principal
prognostic biomarkers of disease progression [17,18]. Radiological
features include pleural fibrotic thickening and subpleural fi-
broelastosis, with an upper lobe predominance associated with traction
bronchiectasis, architectural distortion, loss of volume and reticulations
[17–22]. In advanced stages of disease, the architectural distortion can
involve also adjacent and lower lobes. Histopathologic features include
aggregates of elastic fibers, especially in the sub-pleural areas, and
intra-alveolar collagenous fibrosis with septal elastosis (with or without
collagenous thickening of the visceral pleura) [20,22]. The interface
with uninvolved parenchyma is typically abrupt; the architectural dis-
tortion mainly occurs in sub-pleural areas but a peri-bronchial dis-
tribution has also been reported [21]. PPFE diagnostic criteria have
been postulated only 2 years ago and include the detection of multi-
lobar subpleural and/or centrilobular fibrous interstitial pneumonia
with an extensive (> 80%) proliferation of elastic fibers in non-at-
electasis lung [22].
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Here, we report for the first time the case of a patient affected by
Giant Cell Arteritis with histologically proven PPFE.
2. Case report
2.1. Clinical and functional parameters
A 63 years old never smoker male patient, with no professional
exposure (hunter for hobby) and a positive family history for IPF (his
brother died for acute exacerbation of IPF), was referred to the emer-
gency room of our Centre reporting asthenia, fever and recurrent epi-
sodes of headache in the last seven months. A physical examination
revealed no remarkable clinical signs, including normal chest sounds.
The patient had no evidence of cutaneous or ocular disease. Brain MRI
was normal as well as FDG PET/CT.
Giant Cell Arteritis (GCA) was hypothesized according to rheuma-
tologic evaluation, increased serum C-reactive protein levels (8.06 mg/
dl) and neutrophilic leucocytosis. During the hospitalization, the pa-
tient had an episode of amaurosis fugax and “Horton's Arteritis” diag-
nosis was confirmed. He was treated with oral steroids and metho-
trexate: however, after 2 months of treatment was referred to the
pulmonology unit for a persistent dry cough and recurrent fever.
Physical examination was normal; lung function tests revealed a mild
functional restrictive impairment (FVC 81%, FEV1 80%, TLC 67% of
predicted values) associated with a severe reduction of carbon mon-
oxide diffusion (39% of predicted value).
2.2. Radiological features
Chest X-ray revealed widespread accentuation of the pulmonary
interstitium.
High-resolution computed tomography (HRCT) showed a micro-
nodular pattern with peribronchovascular distribution, bilateral intense
pleural and sub-pleural fibrosis, interlobular septal thickening and
traction bronchiectasis, predominantly in the upper lobes. There were
no honeycombing areas. No evidence of disease was found in the
middle and in the lower lobes (Fig. 1).
2.3. Laboratory data
C-reactive protein levels were still increased (4.62 mg/100 ml);
ACE, lysozyme and chitotriosidase were in the normal range. No ser-
ological evidence of connective tissue disease was found. Diagnostic
bronchoscopy was performed: the analysis of bronchoalveolar lavage
fluid (BAL) showed normal microbiological condition. The cellular
analysis of BAL showed 2.800.000 total cells, with a percentage of 46%
macrophages, 45% lymphocytes with CD4/CD8 ratio 2.49, and 9%
neutrophils.
2.4. Histological evaluation
The patient stopped methotrexate and continued steroid therapy
and empiric antibiotics; however, in the following three months, he still
referred dry cough, unresponsive to steroids and other treatments.
Subsequently, the patient underwent a surgical lung biopsy (VATS) and
histological observations with light scattering spectroscopy (LSS)
showed dense collagenous fibrosis with concomitant elastosis of the
visceral pleura and the lung parenchyma, affecting peribronchial and
peribronchiolar tissue. Visceral pleura was highly thickened by a mix-
ture of elastic and dense collagen fibers. Mild deposition of silica was
observed without non-necrotizing granulomas (Figs. 2 and 3).
After the multidisciplinary discussion for the evaluation of clinical,
radiological and histological features of the patients, the diagnosis of
PPFE was confirmed.
3. Discussion
PPFE has never been associated with giant cell arteritis and, as far as
we know, only two GCA patients with interstitial lung diseases have
been described in the literature. Karam et al., in 1982 reported a case of
a patient with GCA without specific interstitial lung involvement and
no PPFE evidence [23] while more recently Konoshi et al. described a
clinical case without PPFE evidence at HRCT [24]. The lung involve-
ment in GCA is rare and interstitial lung diseases (ILD) are usually re-
ported as an uncommon clinical manifestation of GCA [25]. Our patient
is probably the first case presenting PPFE associated with GCA and we
wonder if this is a real associative disease or a coincidence, perhaps
secondary to drug effects.
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Fig. 1. HRCT axial images (a, b) and sagittal multiplanar reconstructions (c) show pleuroparenchymal fibroelastosis, involving the dorsal regions of upper lobes
(arrows) and the right fissure (arrowhead).
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Fig. 2. Histological evaluation of VATS sampling. Pleural fibroelastosys clearly separated from lung parenchymal tissue (on the left, hematoxylin-eosin staining; on
the right, Weigert staining).
Fig. 3. PPFE infiltration of lung parenchyma (on the left, hematoxylin-eosin staining; on the right, Weigert staining).
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